Hans Jurgen Mager

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

Elisabetta Buscarini, Luisa M. Botella, Urban W. Geisthoff et al. · Orphanet Journal of Rare Diseases · 2019 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)

Claire L. Shovlin, Elisabetta Buscarini, Anette Drøhse Kjeldsen et al. · Orphanet Journal of Rare Diseases · 2018 · 94 citations · Full text

Medicine, Surgery, Clinical Epidemiology +14

The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care

Claire L. Shovlin, Elisabetta Buscarini, Carlo Sabbà et al. · European Journal of Medical Genetics · 2021 · 54 citations · Full text

Medicine, Surgery, Clinical Medicine +12

European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)

Omer Eker, Edoardo Boccardi, Ulrich Sure et al. · Orphanet Journal of Rare Diseases · 2020 · 45 citations · Full text

Medicine, Neurology, Neurosurgery +17